Geron Corporation (GERN)

Etorro trading 970x250
Geron Corporation (GERN) Logo

About Geron Corporation

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California. Address: 919 East Hillsdale Boulevard, Foster City, CA, United States, 94404

Geron Corporation News and around…

Latest news about Geron Corporation (GERN) common stock and company :

Geron to Present at the H.C. Wainwright BioConnect Conference
04 Jan, 2022 FinancialContent

Geron to Present at the H.C. Wainwright BioConnect Conference

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16 Dec, 2021 FinancialContent

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Geron Reports Presentations at American Society of Hematology Annual Meeting
14 Dec, 2021 FinancialContent

Geron Reports Presentations at American Society of Hematology Annual Meeting

Geron Announces Appointment of Chief Business Officer
02 Dec, 2021 FinancialContent

Geron Announces Appointment of Chief Business Officer

12 Health Care Stocks Moving In Wednesday's After-Market Session
17 Nov, 2021 FinancialContent

Gainers Rani Therapeutics Hldgs (NASDAQ:RANI) stock rose 7.36% to $35.0 during Wednesday's after-market session. The ...

Geron to Present at the Stifel 2021 Virtual Healthcare Conference
12 Nov, 2021 FinancialContent

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, will present a company overview at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 2:40 p.m. ET.

30 Stocks Moving in Wednesday's Pre-Market Session
10 Nov, 2021 FinancialContent

Gainers RenovoRx, Inc. (NASDAQ: RNXT) rose 113% to $11.50 in pre-market trading. The company, on Tuesday evening, made a ...

Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates
10 Nov, 2021 Yahoo! Finance

Geron (GERN) delivered earnings and revenue surprises of 11.11% and 9.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Geron Presents Investor Event Highlights
09 Nov, 2021 FinancialContent

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, summarized key highlights from its Investor Event held on November 9. An archive of the presentation webcast is available through the Investor Relations section of Geron’s website under Events. The Company also reported its financial results for the third quarter and year to date 2021 periods. As of September 30, 2021, the Company had $215.8 million in cash and marketable securities. These financial resources, combined with expected future non-dilutive funding under a current debt facility, are expected to be sufficient to fund current operations, including the new programs presented at the Investor Event, through the end of the first quarter of 2023.

Geron Announces Imetelstat Presentations at Upcoming American Society of Hematology Annual Meeting
04 Nov, 2021 FinancialContent

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that three abstracts related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted as poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting to be held from December 11-14, 2021. The abstracts are available on the ASH website at www.hematology.org.

Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2021
02 Nov, 2021 FinancialContent

Upgrades UBS upgraded the previous rating for ONE Gas Inc (NYSE:OGS) from Neutral to Buy. For the third quarter, ONE Gas ...

12 Health Care Stocks Moving In Monday's After-Market Session
01 Nov, 2021 FinancialContent

Gainers Biophytis (NASDAQ:BPTS) shares moved upwards by 37.54% to $8.5 during Monday's after-market session. The market value of ...

Is Geron (NASDAQ:GERN) Using Debt In A Risky Way?
31 Oct, 2021 Yahoo! Finance

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Analysts Estimate Geron (GERN) to Report a Decline in Earnings: What to Look Out for
28 Oct, 2021 Yahoo! Finance

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Geron Enters New Innovative Licensing and Access Pathway in the United Kingdom for Imetelstat
25 Oct, 2021 FinancialContent

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that imetelstat, the Company’s first in class telomerase inhibitor, has been granted an Innovation Passport, which is the first prescribed entry point to the Innovative Licensing and Access Pathway (ILAP) launched in the United Kingdom (UK) by the Medicines and Healthcare products Regulatory Agency (MHRA) in January 2021, post-Brexit. The objective of this new licensing and access pathway is to reduce the time to market for innovative medicines. Key benefits of being within ILAP include a 150-day accelerated assessment and rolling review of a Marketing Authorization Application (MAA), as well as opportunities for frequent interactions with the review staff at the MHRA and its partner agencies, including the National Institute for Health and Care Excellence (NICE), to discuss imetelstat’s development, regulatory plans and reimbursement plans.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Oct, 2021 FinancialContent

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
18 Oct, 2021 FinancialContent

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). Based upon current planning assumptions, Geron expects top-line results for IMerge Phase 3 to be available at the beginning of January 2023.

Geron to Host a Virtual Investor Event in November
15 Oct, 2021 FinancialContent

Geron to Host a Virtual Investor Event in November

First Week of June 2022 Options Trading For Geron
15 Oct, 2021 FinancialContent

Investors in Geron Corp. (GERN) saw new options begin trading this week, for the June 2022 expiration..

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
12 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We're getting right into the thick of it today with a look at the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

15 Stocks Moving in Tuesday's Pre-Market Session
12 Oct, 2021 FinancialContent

Gainers Quanterix Corporation (NASDAQ: QTRX) shares rose 17.6% to $48.55 in pre-market trading after the company announced its ...

Geron Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology
11 Oct, 2021 FinancialContent

Geron Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology

Geron Earnings Perspective: Return On Capital Employed
04 Oct, 2021 FinancialContent

Benzinga Pro data, Geron (NASDAQ:GERN) reported Q2 sales of $107.00 thousand. Earnings fell to a loss of $28.89 million, resulting in ...

First Week of January 2024 Options Trading For Geron
14 Sep, 2021 FinancialContent

Investors in Geron Corp. (GERN) saw new options begin trading this week, for the January 2024 expiration..

Geron Announces September Investor Conference Presentation Webcasts
01 Sep, 2021 FinancialContent

Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences:

Here's What Investors Need From Geron
28 Aug, 2021 FinancialContent

It could be a while before Geron has a big catalyst.

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Geron (GERN) Q2 2021 Earnings Call Transcript
17 Aug, 2021 FinancialContent

GERN earnings call for the period ending June 30, 2021.

Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
16 Aug, 2021 Yahoo! Finance

Geron (GERN) delivered earnings and revenue surprises of 0.00% and 33.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Geron Corporation (GERN) is a NASDAQ Common Stock listed in , ,

970x250